Antibodies Used for Immunochemistry and Lineage Allocation of EBV-Infected Cells in TW and PMBCs Obtained From Patients With IM
| Antibody Designation . | Cluster of Differentiation . | Specificity . | Source . |
|---|---|---|---|
| βF1* | T-cell receptor β chain | T-Cell Sciences (Cambridge, MA) | |
| CD3* (polyclonal) | CD3 | Pan T cell | DAKO (Glostrup, Denmark) |
| CD8* | CD8 | T-cell subset | DAKO |
| L26* | CD20 | Pan B cell | DAKO |
| Ki-B3 | CD45RA | B-cell subset, including certain plasmablasts and proplasma cells | Lab. of Dr. Parwaresch (Kiel, Germany) |
| BZ.1† | EBV-encoded lytic phase BamHI Z (BZLF1) trans-activator protein (ZEBRA) | DAKO |
| Antibody Designation . | Cluster of Differentiation . | Specificity . | Source . |
|---|---|---|---|
| βF1* | T-cell receptor β chain | T-Cell Sciences (Cambridge, MA) | |
| CD3* (polyclonal) | CD3 | Pan T cell | DAKO (Glostrup, Denmark) |
| CD8* | CD8 | T-cell subset | DAKO |
| L26* | CD20 | Pan B cell | DAKO |
| Ki-B3 | CD45RA | B-cell subset, including certain plasmablasts and proplasma cells | Lab. of Dr. Parwaresch (Kiel, Germany) |
| BZ.1† | EBV-encoded lytic phase BamHI Z (BZLF1) trans-activator protein (ZEBRA) | DAKO |